Norwegian SmPC
The current Norwegian Summary of Product Characteristics, including indication, dosage, contraindications, warnings and pharmacological information.
Open approved SmPC ↗Professional information
Approved product information and scientific resources.
A structured starting point for healthcare professionals, licensing partners and other qualified stakeholders evaluating Coxor®.
How to use this page
Start with the approved information for your market.
Product information, prescribing status and administrative requirements may differ between countries. Always use the locally approved product information and follow applicable national requirements.
Important
This resource page does not replace the approved product information, package leaflet, medical advice or local regulatory requirements. For questions about a specific market, contact Asamedic Regulatory Affairs.
Core product documents
Official information for Coxor® 300 mg.
Norwegian product entry
Felleskatalogen provides the Norwegian product entry, package information, dispensing status and links to approved documentation.
Open Felleskatalogen ↗Consumer information
The Coxor® consumer site provides the approved patient-facing information and instructions for use in Norway.
Open Coxor.no ↗Scientific evidence
Publication and evidence context.
Published Coxor® study
A randomized, open-label, two-arm crossover study comparing the pharmacokinetic profile of a 300 mg oral aspirin solution with a chewed aspirin tablet.
View PubMed record ↗Evidence boundaries
The study assessed pharmacokinetic exposure in healthy subjects. It was not designed to establish clinical outcome benefit in patients with acute myocardial infarction.
Review the evidence summaryAdditional documentation
For market-specific regulatory, quality, manufacturing or commercial documentation, contact the Asamedic team directly.
Contact Regulatory AffairsMarket-specific support
Need a specific document or market package?
Asamedic can provide additional information to qualified partners and stakeholders, subject to the applicable confidentiality and regulatory framework.
Request information